// App-Quantinova.ai

182 : Correlation between radiographic progression-free survival (rPFS) and overall survival (OS): Results from PREVAIL.

Researchers

Presenter

  • Michael J. Morris

Principal Investigators

  • Tomasz M. Beer

  • Yohann Loriot

  • Celestia S. Higano

  • Andrew J. Armstrong

  • Cora N. Sternberg

  • Johann S. De Bono

  • Bertrand F. Tombal

  • Teresa Parli

  • Suman Bhattacharya

  • Andrew P. Krivoshik

  • De Phung

  • Dana E. Rathkopf

Medical Centers

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, OR

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Seattle Cancer Care Alliance/University of Washington, Seattle, WA

  • Duke University Medical Center, Duke Cancer Institute Divisions of Medical Oncology and Urology, Duke University, Durham, NC

  • San Camillo-Forlanini Hospital, Rome, Italy

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Cliniques Universitaires Saint-Luc, UCL, Brussels, MN, Belgium

  • Medication, Inc., San Francisco, CA

  • Medication, Inc., San Francisco, CA

  • Astellas Pharma Global Development, Inc., Northbrook, IL

  • Astellas Pharma Global Development, Leiden, Netherlands

Locations

  • United States

  • France

  • Italy

  • United Kingdom

  • Belgium

  • Netherlands

Companies

  • Medivation, Inc.

  • Astellas Pharma US,

Study Components

Therapeutic Area

  • Musculoskeletal

  • Genetic Disorder

Disease

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01212991

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved